Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 63.21 Billion JPY | 113.87% |
| 2022 | 29.55 Billion JPY | 1.65% |
| 2021 | 29.07 Billion JPY | 76.73% |
| 2020 | 16.45 Billion JPY | 865.55% |
| 2019 | 1.7 Billion JPY | -56.75% |
| 2018 | 3.94 Billion JPY | -36.23% |
| 2017 | 6.17 Billion JPY | 25.82% |
| 2016 | 4.91 Billion JPY | -28.29% |
| 2015 | 6.84 Billion JPY | 0.0% |
| 2014 | - JPY | 0.0% |
| 2013 | - JPY | 0.0% |
| 2012 | - JPY | 0.0% |
| 2011 | - JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| 2009 | - JPY | 0.0% |
| 2008 | - JPY | 0.0% |
| 2007 | - JPY | 0.0% |
| 2006 | - JPY | 0.0% |
| 2005 | - JPY | 0.0% |
| 2004 | - JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 59.09 Billion JPY | -2.27% |
| 2024 Q2 | 60.47 Billion JPY | -2.22% |
| 2024 Q1 | 61.84 Billion JPY | -2.17% |
| 2023 Q3 | 66.69 Billion JPY | 120.3% |
| 2023 Q4 | 63.21 Billion JPY | -5.22% |
| 2023 FY | 63.21 Billion JPY | 113.87% |
| 2023 Q2 | 30.27 Billion JPY | 1.9% |
| 2023 Q1 | 29.71 Billion JPY | 0.52% |
| 2022 FY | 29.55 Billion JPY | 1.65% |
| 2022 Q4 | 29.55 Billion JPY | 0.27% |
| 2022 Q1 | 29.28 Billion JPY | 0.73% |
| 2022 Q2 | 29.43 Billion JPY | 0.5% |
| 2022 Q3 | 29.47 Billion JPY | 0.15% |
| 2021 FY | 29.07 Billion JPY | 76.73% |
| 2021 Q1 | 16.61 Billion JPY | 0.95% |
| 2021 Q2 | 16.63 Billion JPY | 0.17% |
| 2021 Q3 | 28.93 Billion JPY | 73.92% |
| 2021 Q4 | 29.07 Billion JPY | 0.49% |
| 2020 Q2 | 1.5 Billion JPY | -3.41% |
| 2020 Q1 | 1.55 Billion JPY | -8.86% |
| 2020 Q4 | 16.45 Billion JPY | 0.69% |
| 2020 FY | 16.45 Billion JPY | 865.55% |
| 2020 Q3 | 16.34 Billion JPY | 989.33% |
| 2019 Q3 | 3.24 Billion JPY | -20.01% |
| 2019 FY | 1.7 Billion JPY | -56.75% |
| 2019 Q2 | 4.05 Billion JPY | -17.42% |
| 2019 Q1 | 4.91 Billion JPY | 0.0% |
| 2019 Q4 | 1.7 Billion JPY | -47.5% |
| 2018 Q1 | 6.17 Billion JPY | -10.59% |
| 2018 Q3 | 4.75 Billion JPY | -12.62% |
| 2018 Q2 | 5.44 Billion JPY | -11.9% |
| 2018 FY | 3.94 Billion JPY | -36.23% |
| 2017 Q1 | 4.91 Billion JPY | -9.01% |
| 2017 FY | 6.17 Billion JPY | 25.82% |
| 2017 Q4 | 6.91 Billion JPY | -9.57% |
| 2017 Q3 | 7.64 Billion JPY | -8.28% |
| 2017 Q2 | 8.33 Billion JPY | 69.67% |
| 2016 FY | 4.91 Billion JPY | -28.29% |
| 2016 Q4 | 5.39 Billion JPY | -8.23% |
| 2016 Q1 | 6.84 Billion JPY | -6.58% |
| 2016 Q3 | 5.88 Billion JPY | -7.61% |
| 2016 Q2 | 6.36 Billion JPY | -7.05% |
| 2015 Q2 | - JPY | 0.0% |
| 2015 FY | 6.84 Billion JPY | 0.0% |
| 2015 Q3 | 7.8 Billion JPY | 0.0% |
| 2015 Q4 | 7.32 Billion JPY | -6.15% |
| 2015 Q1 | - JPY | -100.0% |
| 2014 Q4 | 15 Million JPY | 0.0% |
| 2014 Q3 | - JPY | 0.0% |
| 2014 Q2 | - JPY | 0.0% |
| 2014 Q1 | - JPY | 0.0% |
| 2014 FY | - JPY | 0.0% |
| 2013 FY | - JPY | 0.0% |
| 2013 Q1 | - JPY | 0.0% |
| 2013 Q2 | - JPY | 0.0% |
| 2013 Q4 | - JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q1 | -11.9 Million JPY | 0.0% |
| 2012 FY | - JPY | 0.0% |
| 2012 Q4 | - JPY | 0.0% |
| 2012 Q2 | - JPY | 100.0% |
| 2011 FY | - JPY | 0.0% |
| 2011 Q4 | - JPY | 0.0% |
| 2011 Q1 | - JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2010 FY | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q1 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | - JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| 2008 Q4 | - JPY | 0.0% |
| 2008 FY | - JPY | 0.0% |
| 2007 FY | - JPY | 0.0% |
| 2006 FY | - JPY | 0.0% |
| 2005 FY | - JPY | 0.0% |
| 2004 FY | - JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 767.03 Million JPY | -8141.486% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 2 Billion JPY | -3060.75% |
| Linical Co., Ltd. | 1.49 Billion JPY | -4114.474% |
| Trans Genic Inc. | 1.32 Billion JPY | -4663.48% |
| MEDINET Co., Ltd. | 781 Thousand JPY | -8094010.115% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.34 Billion JPY | -2593.348% |
| AnGes, Inc. | 214.94 Million JPY | -29309.302% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -59062.931% |
| Immuno-Biological Laboratories Co., Ltd. | 84.56 Million JPY | -74656.685% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | -5600.612% |
| Carna Biosciences, Inc. | 28.4 Million JPY | -222472.354% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 875.59 Million JPY | -7119.637% |
| RaQualia Pharma Inc. | 39.05 Million JPY | -161782.202% |
| Chiome Bioscience Inc. | - JPY | -Infinity% |
| Kidswell Bio Corporation | 1.83 Billion JPY | -3339.411% |
| PeptiDream Inc. | 19.63 Billion JPY | -221.96% |
| Oncolys BioPharma Inc. | 161.1 Million JPY | -39139.603% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 397 Million JPY | -15823.174% |
| Healios K.K. | 450 Million JPY | -13947.778% |
| BrightPath Biotherapeutics Co., Ltd. | - JPY | -Infinity% |
| Kubota Pharmaceutical Holdings Co., Ltd. | - JPY | -Infinity% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 77.29 Million JPY | -81688.307% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 773.29 Million JPY | -8074.79% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 788 Million JPY | -7922.208% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 491.35 Million JPY | -12765.548% |
| StemCell Institute Inc. | 6.67 Million JPY | -946799.341% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 143.75 Million JPY | -43875.652% |